race oncology secures governance approval for open-label zantrene trial
Published 2 years ago • 1K plays • Length 5:00Download video MP4
Download video MP3
Similar videos
-
5:40
race oncology ltd advances zantrene aml trials
-
0:36
race trials new zantrene drug for extramedullary acute myeloid leukaemia (emd aml) – animation
-
0:41
race oncology achieves promising results in phase 1a-b clinical trial
-
6:49
race oncology receives positive results from aml trial of bisantrene
-
4:36
race oncology partners with george clinical for rc220 bisantrene trials
-
5:40
race oncology discusses clinical progress and march quarter highlights
-
2:48:24
clinical updates in lung cancer, breast cancer, gi, gu & haematological malignancies - day 2
-
47:26
post ash22 mds summary
-
48:49
is mds cancer? navigating your mds diagnosis | dr. david swoboda
-
2:45
race oncology welcomes positive pre-ind meeting for zantrene
-
3:15
race oncology reports final data from preclinical melanoma research program
-
7:33
race oncology fields promising early results from zantrene kidney cancer program
-
7:14
race oncology with proactive at the asx small and mid-cap conference
-
1:44
fast facts about the regulatory approval pathway for biosimilars – amgen science
-
6:42
race oncology (asx: rac) reveals breakthrough chemotherapy heart protection discovery for zantrene®
-
5:10
race oncology receives fda orphan drug designation extension for bisantrene rc220
-
8:00
race oncology highlights impressive bisantrene clinical data
-
13:32
race oncology asx small and mid cap conference
-
4:16
race oncology's breakthrough in cancer cell treatment
-
6:42
race oncology looks to accelerate clinical development of bisantrene